119th Congress · introduced in the House · Mar 19, 2026
END 7-OH Act
Official title from Congress.gov
Latest action (Mar 19, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Crime and Law Enforcement
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
5 citations.
OUTPOST BRANDS, LLC · lobbying firm or registrant: AKIN GUMP STRAUSS HAUER & FELD
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Manufacturing
$160,000
Paid to lobbying firm
Issues related to FDA regulatory legislation, including H.R. 8000 - END 7-OH Act; Issues related to FDA and DEA regulatory action, including on 7-OH
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STUDENTS FOR SENSIBLE DRUG POLICY · lobbying firm or registrant: STUDENTS FOR SENSIBLE DRUG POLICY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Civil Rights/Civil Liberties
Amount not reported
…of the hemp ban by two years, from Nov. 12, 2026 to Nov. 12, 2028. It contains no additional regulatory provisions. The End Needless Distribution of 7-OH Act (H.R. 8000): restricting the distribution of synthetic 7-OH products by treating them as federally controlled substance with no accepted medical use. (OPPOSED)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
STUDENTS FOR SENSIBLE DRUG POLICY · lobbying firm or registrant: STUDENTS FOR SENSIBLE DRUG POLICY
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Civil Rights/Civil Liberties
$30,000
Spent on own lobbying
…of the hemp ban by two years, from Nov. 12, 2026 to Nov. 12, 2028. It contains no additional regulatory provisions. The End Needless Distribution of 7-OH Act (H.R. 8000): restricting the distribution of synthetic 7-OH products by treating them as federally controlled substance with no accepted medical use. (OPPOSED)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
OUTPOST BRANDS, LLC · lobbying firm or registrant: AKIN GUMP STRAUSS HAUER & FELD
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Manufacturing
$160,000
Paid to lobbying firm
Issues related to FDA regulatory legislation, including H.R. 8000 - END 7-OH Act; Issues related to FDA and DEA regulatory action on 7-OH.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STUDENTS FOR SENSIBLE DRUG POLICY · lobbying firm or registrant: STUDENTS FOR SENSIBLE DRUG POLICY
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 12, 2026 · issue area: Civil Rights/Civil Liberties
Amount not reported
…es Act, expunging certain past convictions, and reinvesting in communities disproportionately harmed by prohibition. The End Needless Distribution of 7-OH Act (H.R. 8000): Issues related to restricting the distribution of synthetic 7-OH products by treating them as a federally controlled substance with no accepted medical use.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing